The Steering Committee (SC) consists of all WP leaders and a representative at concentris and meets twice a year. It is the supervisory body where all technical details of the work are discussed. It is responsible for the successful implementation of the project regarding its schedule, budget and expected scientific quality. The SC is furthermore in charge of the preparation and execution of the decisions of the General Assembly.

1. Catharina Hartman, Professor, Department of Psychiatry, University Medical Center Groningen, Netherlands
2. Bru Cormand, Professor, Academic Secretary of the Dept. of Genetics, University of Barcelona, Spain
3. Johannes Thome, Professor, Chair of Dept. of the Clinic and Policlinic of Psychiatry and Psychotherapy, University Medicine Rostock, Germany
4. Andreas Reif, Professor, Chair of Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Germany
5. Ulrich Ebner-Priemer, Professor, Chair of Applied Psychology, Karlsruhe Institute of Technology, Germany
6. Christine Freitag, Professor, Chair of Dept. of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Germany
7. Jan Haavik, Professor, Head of Research Centre, Department of Biomedicine, University of Bergen, Norway
8. Stephen Faraone, Professor, Distinguished Professor, Director of the Dept. of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, US
9. Barbara Franke, Professor, Head of the Research lab for Multifactorial Diseases at the department of Human Genetics, Radboud University Medical Centre, Netherlands
10. Jonna Kuntsi, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK
11. concentris representative: Mary Gazea, Dr., concentris research management, Germany

The GA is the ultimate decision-making body of the Consortium and meets once a year. It consists of one representative of each partner and two of the coordinator with authority to vote, as well as a number of non-voting researchers and graduate students working for CoCA. The GA receives regularly status updates from all work packages, provides scientific and political directions and settles any dispute that might occur. It decides upon all issues involving changes to the content of the project, finances and intellectual property rights. It is in charge of making decisions of major and strategic relevance, either on its own initiative or as proposed by any of the partners or the Steering Committee.

The internal ethics board is a consultative body, which is formed to ensure and improve the ethical components within CoCA. The members of the internal ethics board will be present at the annual GA meetings and will consider and mention any ethical issues which might require (stronger) attention within CoCA.

1. Andreas Reif , Professor, Chair of Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Germany
2. Christine Freitag, Professor, Chair of Dept. of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Germany
3. Jan Buitelaar, Professor of Psychiatry and Child and Adolescent Psychiatry, Radbound University Medical Center, Netherlands
4. Johannes Thome,  Professor, Chair of Dept. of the Clinic and Policlinic of Psychiatry and Psychotherapy, University Medicine Rostock, Germany
5. Jonna Kuntsi,  Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK
6. Jaanus Harro,   Professor, Head of Division of Neuropsychopharmacology, University of Tartu, Estonia
7. Anders Børglum,  Professor, Director of Centre for Integrative Sequencing, Aarhus University

The SEAB is a consultative body, which is formed to ensure and improve the scientific performance and the quality of results of CoCA. The members of the SEAB will be invited to the annual GA meetings in order to monitor the progress of work, to assess the scientific quality and to give feed-back to the Consortium members. The SEAB will also consider and mention any ethical issues which might require (stronger) attention in their feed-back. It has an independent advisory position that includes possible reporting of critical issues the EC, so that safeguarding of the project is ensured.

The DSMC will review any issues concerning the safety of the trial participants (by reviewing serious adverse events) as well as the integrity of the data and possible statistical problems such as selection bias, cross-over, failure to diagnose, failure to treat or failure to follow-up. The DSMC will meet once a year and advise the Steering Committee and the Coordinator/WP leader of the clinical trial on any critical issue.

The Impact Board is responsible for designing a structured communication plan for dissemination and the exploitation of program results and will monitor the steps being taken. Together with the Project Management Office it will oversee the comprehensive internal and external dissemination of project results and knowledge.

1. Barbara Franke, Professor, Head of the Researchlab for Multifactorial Diseases at the department of Human Genetics, Radboud University Medical Centre, Netherlands
2. Andreas Reif, Professor, Chair of Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Germany
3. Catharina Hartman, Professor, Department of Psychiatry, University Medical Center Groningen, Netherlands
4. Ulrich Ebner-Priemer, Professor, Chair of Applied Psychology, Karlsruhe Institute of Technology, Germany
5. Stephen Faraone, Professor, Distinguished Professor, Director of the Dept. of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University
6. Christine Freitag, Professor, Chair of Dept. of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Germany
7. Jan Haavik, Professor, Head of Research Centre, Department of Biomedicine, University of Bergen, Norway
8. Philip Asherson, Professor, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK
9. Christoph Bischoff-Everding, Dr, CEO, HGC GesundheitsColsult GmbH, Germany
10. Junior’s representative: Adrian Muntaner, Dr., Faculty of Sport Sciences and Research Institute of Sports and Health, University of Granada, Spain
11. Junior’s representative: Anna Rommel, Dr., Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK
12. concentris representative: Mary Gazea, Dr., concentris research management, Germany